Surendra K. Ajjarapu
Surendra K. Ajjarapu's purchase track record
Surendra K. Ajjarapu has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2022 | SCNX | $130.00M | +0.8% | -49.6% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
SCNX Shares Drop 19% After Hours Amid Reverse Split. SCNX shares fell 19% in after‑hours trading after the company announced a reverse stock split. The reverse split will consolidate shares, potentially raising the share price but also reducing the number of shares outstanding. The drop comes while the stock sits near its 12‑month low and has a very low RSI, indicating a possible oversold condition. The reverse split may be a move to meet listing requirements and support future trading.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tevogen Regains Nasdaq Listing Compliance. Tevogen Inc. has regained compliance with Nasdaq Global Market continued listing requirements. This development addresses potential delisting risks associated with the company's stock status. The news provides regulatory clarity for the ticker, which has seen significant price volatility over the past year.
Transaction History
| MEDS | ▼ Sell | Other | 100,000 | $500 | 6/22/2026 | View on chart |
| MEDS | ▲ Buy | Grant | 5,000,000 | $1.0M | 3/31/2026 | View on chart |
| MEDS | ▲ Buy | Grant | 2,882,247 | $0 | 3/21/2025 | View on chart |
| MEDS | ▲ Buy | Grant | 600,000 | $0 | 3/21/2025 | View on chart |
| MEDS | ▲ Buy | Grant | 600,000 | $0 | 3/21/2025 | View on chart |
| SCNX | ▲ Buy | Grant | 150,000 | $0 | 1/5/2024 | View on chart |
| TVGN | ▲ Buy | Grant | 1,000,000 | — | 6/7/2023 | View on chart |
| SCNX | ▲ Buy | Grant | 51,724 | $0 | 9/1/2022 | View on chart |
| SCNX | ▲ Buy | Open Market | 10,000 | $130.0M | 5/20/2022 | View on chart |
| SCNX | ▼ Sell | Other | 201,613 | — | 6/12/2020 | View on chart |
| SCNX | ▲ Buy | Grant | 74,484 | $456K | 4/14/2020 | View on chart |
| SCNX | ▲ Buy | Grant | 49,020 | $300K | 4/14/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MEDS hits $1M monthly Corexa revenue, unveils health app
DataMeds AI reported that its Corexa Pharmacy generated over $1 million in revenue for the month, reflecting a 66% increase in sales. The company also introduced the Health Lives Here app, which targets GLP‑1 telehealth and pharmacy services. The announcements coincided with a reported rise in the stock price following the app launch.
MEDS hits $1M monthly Corexa revenue, unveils health app. DataMeds AI reported that its Corexa Pharmacy generated over $1 million in revenue for the month, reflecting a 66% increase in sales. The company also introduced the Health Lives Here app, which targets GLP‑1 telehealth and pharmacy services. The announcements coincided with a reported rise in the stock price following the app launch.